Adherex Technologies (NASDAQ:FENC – Get Free Report)‘s stock had its “buy” rating reissued by analysts at B. Riley Financial in a research note issued to investors on Monday, Benzinga reports. They presently have a $19.00 target price on the stock, up from their previous target price of $18.00. B. Riley Financial‘s target price would indicate a potential upside of 63.51% from the stock’s current price.
Several other analysts also recently weighed in on the stock. Wedbush lifted their target price on shares of Adherex Technologies from $13.00 to $16.00 and gave the company an “outperform” rating in a report on Wednesday, August 12th. Zacks Research upgraded shares of Adherex Technologies from a “hold” rating to a “strong-buy” rating in a research report on Thursday. Weiss Ratings upgraded shares of Adherex Technologies from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Friday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Adherex Technologies in a report on Wednesday, September 9th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, Adherex Technologies presently has an average rating of “Buy” and an average target price of $17.25.
Get Our Latest Report on Adherex Technologies
Adherex Technologies Price Performance
NASDAQ FENC opened at $11.62 on Monday. The business’s 50-day moving average price is $10.64 and its 200 day moving average price is $9.36. The firm has a market cap of $409.26 million, a P/E ratio of 1,162.00 and a beta of 1.29. Adherex Technologies has a 52-week low of $5.65 and a 52-week high of $13.25.
Adherex Technologies (NASDAQ:FENC – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported $0.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.10 by $0.02. Adherex Technologies had a return on equity of 8.96% and a net margin of 2.52%. The company had revenue of $19.61 million during the quarter, compared to analysts’ expectations of $18.87 million. As a group, analysts anticipate that Adherex Technologies will post 0.32 earnings per share for the current year.
Insider Buying and Selling at Adherex Technologies
In other Adherex Technologies news, insider Pierre Sargis Sayad sold 12,000 shares of the firm’s stock in a transaction on Monday, August 31st. The stock was sold at an average price of $12.18, for a total value of $146,160.00. Following the completion of the sale, the insider owned 9,519 shares of the company’s stock, valued at approximately $115,941.42. This trade represents a 55.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Robert Andrade sold 75,000 shares of the firm’s stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $11.78, for a total value of $883,500.00. Following the completion of the sale, the chief financial officer directly owned 217,675 shares of the company’s stock, valued at approximately $2,564,211.50. This trade represents a 25.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 10.73% of the company’s stock.
About Adherex Technologies
Adherex Technologies was a biotechnology company focused on developing treatments for cancer. In 2014, the company changed its name to Fennec Pharmaceuticals Inc.; Fennec later adopted the Nasdaq ticker FENC. Fennec is a commercial-stage biopharmaceutical company focused on therapies that address complications of cancer treatment. Its principal product is PEDMARK, a sodium thiosulfate injection approved in the United States to reduce the risk of cisplatin-related hearing damage in certain pediatric patients with cancer.
Recommended Stories
- Five stocks we like better than Adherex Technologies
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
Receive News & Ratings for Adherex Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adherex Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
